Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)
Sandostatin, Sandostatin LAR ®
Octreotide and lanreotide are recommended for the treatment of secretory gastrointestinal disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea). Initiation and continued supply of octreotide/lanreotide is the responsibility of hospital or specialist services.
Octreotide and lanreotide are not licensed for this indication and there is not a large body of evidence to support this unlicensed use.
Patients should be reviewed within 4 weeks of initiation of somatostatin analogues. Continuation of treatment should only be recommended if clinicians judge that patients have derived a meaningful response from somatostatin treatment (reduced stoma output, stool volume and progression towards closure of fistulas).
Reason for decision: